Noopept vs Oxiracetam
Moderate Research vs Moderate Research
compatible Researched · 90% Oxiracetam and Noopept operate through overlapping but distinct mechanisms. Oxiracetam primarily modulates AMPA receptors and cholinergic signaling, while Noopept additionally modulates NMDA receptors and upregulates BDNF and NGF. The combination is well tolerated and commonly used in nootropic stacks. Use standard doses of each, as there is no known pharmacokinetic interaction.
Molecular Data
Noopept Oxiracetam
Weight 318.37 Da 158.15 Da
Half-life ~30 minutes (oral), active metabolite cycloprolylglycine persists longer ~8 hours
Type Dipeptide derivative (C17H22N2O4) Racetam (C6H10N2O3), 4-hydroxy derivative of piracetam
Key Benefits
Noopept
01 Enhanced memory formation and consolidation through upregulation of BDNF and NGF
02 Neuroprotective effects against oxidative stress, excitotoxicity, and amyloid-beta toxicity
03 Improved learning capacity and information retrieval via AMPA/NMDA receptor modulation
04 Ultra-low effective dose (10-30 mg) compared to classical racetams, reducing pill burden and cost
05 Anxiolytic properties observed at standard nootropic doses without sedation
06 Fast onset of subjective effects despite the short parent compound half-life, due to active metabolite persistence
Oxiracetam
01 Enhanced logical reasoning, analytical thinking, and mathematical ability -- the cognitive domains where oxiracetam most clearly outperforms other racetams
02 Improved processing speed and working memory capacity, facilitating technical work and complex problem-solving
03 Mild psychostimulant effect that increases mental alertness without the jitteriness or crash associated with caffeine or amphetamines
04 Strong safety profile with decades of clinical use in Europe and Asia, minimal hepatic metabolism, and low interaction potential
05 Enhanced memory formation and consolidation through AMPA receptor modulation and increased hippocampal acetylcholine release
06 Neuroprotective properties demonstrated in animal models of ischemia and excitotoxic injury
Side Effects
Noopept
Headache (most common side effect, typically caused by insufficient choline intake -- co-supplementation with Alpha-GPC or CDP-Choline usually resolves this)
Irritability and restlessness, particularly at doses exceeding 30 mg/day
Insomnia if taken too late in the day
Mild gastrointestinal discomfort when taken on an empty stomach
Oxiracetam
Headache (the most frequently reported side effect, almost always caused by increased acetylcholine demand outstripping choline supply -- resolved by co-supplementing with Alpha-GPC or CDP-Choline)
Insomnia or sleep disruption when taken too late in the day, due to the mild stimulant effect and 8-hour half-life
Mild anxiety or nervousness, particularly in anxiety-prone individuals or at higher doses
Mild gastrointestinal discomfort, nausea, or diarrhea (uncommon and usually transient)
Contraindications
Known hypersensitivity to Noopept or related compounds
Severe hepatic impairment (metabolized by the liver)
Severe renal impairment
Pregnancy and breastfeeding (insufficient safety data)
Hypertension that is poorly controlled (due to potential mild pressor effects)
Known hypersensitivity to oxiracetam or other racetam compounds
Severe renal impairment (oxiracetam is excreted primarily by the kidneys unchanged)
Pregnancy and breastfeeding (insufficient safety data)
Epilepsy or seizure disorders (racetams may lower the seizure threshold in susceptible individuals, though this risk is considered low with oxiracetam)
Research Evidence
Noopept Oxiracetam
Status Moderate Research Moderate Research
References 4 studies 5 studies
FDA Approved No No
More comparisons: Modafinil
This comparison is for educational and research purposes only. Consult a healthcare professional before use.